

INDESYS Hepatology Club
November 2, 2024

Acute-on-Chronic Liver Failure
Terminology, Epidemiology, Pathophysiology,
Management

Richard Moreau¹⁻³

¹EF CLIF, Barcelona, Spain;

**²Service d'Hépatologie, Hôpital Beaujon, APHP,
Clichy, France;**

**³Centre de Recherche sur l'Inflammation (CRI), INSERM, Université Paris Cité,
Paris, France**

Outline

- **Terminology**
- **Epidemiology**
- **Pathophysiology**
- **Management**
- **Research agenda**

Consortia Which Developed ACLF Definitions

- **EASL-Chronic Liver Failure (CLIF) Consortium**
- **North American Consortium for the Study of End-Stage Liver Disease (NACSELD)**
- **APASL ACLF Research Consortium (AARC)**

Defining Some Terms

- **Acutely decompensated cirrhosis = recent ascites, HE, GI hemorrhage, or any combination of these disorders in patients with cirrhosis**
- **Clinically apparent precipitant of acute decompensation:**
 - **Extrahepatic: acute infection, GI hemorrhage**
 - **Intrahepatic: alcohol-related hepatitis**
 - **See EASL CPG**
- **Short-term mortality rate = % of patients who died within 28 days after enrollment, without having received LTx**

Moreau et al. *Gastroenterology* 2013;144:1426-37.e1-9. EASL CPG. *J Hepatol* 2023;79:461-91.

EASL-CLIF Conducted the CANONIC Study

- **Prospective, European, agnostic, observational study designed to determine criteria for ACLF in patients nonelectively admitted for acutely decompensated cirrhosis**
 - **With or without prior decompensation**
 - **With or without ongoing clinically apparent precipitant(s)**
- **Prespecified:**
 - **Criteria of organ failure (OF) for each of 6 major organ systems**
 - **ACLF should be associated with short-term mortality rate $\geq 15\%$**
- **Data collected on granular eCRF; continuous monitoring by skilled data managers**
- **1,343 patients enrolled in 2011; analyzed in 2011-12.**

The CLIF-C OF Scoring System

Organ System	1 Point	2 Points	3 Points
Liver	Bilirubin <6 mg/dl	Bilirubin 6.0–11.9 mg/dl	Bilirubin ≥12 mg/dl
Kidney	Creatinine <1.5 mg/dl Creatinine 1.5–1.9 mg/dl	Creatinine 2.0–3.4 mg/dl	Creatinine ≥3.5 mg/dl or RRT
Brain (West Haven criteria)	Grade 0	Grade 1–2	Grade 3–4
Coagulation	INR <2.0	INR 2.0–2.4	INR ≥2.5
Circulation	MAP ≥70 mm Hg	MAP <70 mm Hg	Vasopressor requirement
Respiration	Pao ₂ /Fio ₂ >300 Spo ₂ /Fio ₂ >357	Pao ₂ /Fio ₂ 201–300 Spo ₂ /Fio ₂ 215–357	Pao ₂ /Fio ₂ ≤200 Spo ₂ /Fio ₂ ≤214

Jalan, Saliba, Pavesi, et al. J Hepatol 2014;61:1038-47. EASL CPG. J Hepatol 2023;79:461-91.

EASL-CLIF Definition of ACLF

Patient Group	Prevalence	Short-Term Mortality	Assigned Grade
	<i>% of patients</i>		
Absence of OF	68	4.5	Absence of ACLF
Single, nonkidney OF without KD or BD	10	6	
Single KF	7	19	ACLF-1
Single, nonkidney OF with KD or BD	4	28	ACLF-1
Two OFs	7.5	32	ACLF-2
Three OFs	2	68	ACLF-3
Four to 6 OFs	1.5	89	ACLF-3

Markers of Organ Function Associated with Short-Term Mortality in ACLARA (Multivariable Analysis)

Variable at Enrollment	Subdistribution Hazard Ratio (95% CI)
MAP, in 1-mm Hg units	0.99 (0.97 to 1.00)
SpO₂/FiO₂, in 1 units	0.96 (0.95 to 0.98)
Albumin, in 1-g/dl units	0.68 (0.53 to 0.86)
Creatinine, in 1-mg/dl units	1.20 (1.11 to 1.30)
INR, in 1 units	1.41 (1.24 to 1.60)

Farias, Curto Vilalta et al. Gastroenterology 2023;165:696-716.

Database Used by NACSELD

- **Data prospectively collected on a REDCap (Research Electronic Data Capture) tool**
 - **From 2,675 patients**
 - **Nonelectively admitted for acutely decompensated cirrhosis, with or without prior decompensation**
 - **With or without ongoing clinically apparent extra- or intra-hepatic precipitant(s)**
- **Prespecified:**
 - **OF criteria for each of 4 organ systems (kidney, brain, circulation, respiration)**
 - **Liver failure, coagulation failure were not considered.**

OF Diagnosis by NACSELD

- **Kidney: Need for RRT**
- **Brain: HE grade 3 or 4 (West Haven)**
- **Circulation: shock refractory to fluid resuscitation requiring vasopressors**
- **Respiration: Need for bilevel positive airway pressure or mechanical ventilation**

NACSELD focus: severe ICU patients

Bajaj et al. Hepatology 2014;60:250-6. O'Leary et al. Hepatology 2018;67:2367-74.

ACLF Definition by NACSELD

Number of OFs	Probability of Dying by 30 Days
0	4%
1	12%
2	29%
3	54%
4	77%

Bajaj et al. Hepatology 2014;60:250-256.

'Liver-Centric' APASL Definition of ACLF

- **Based on opinion of APASL experts who analyzed a database**
 - **Data collection (eCRF?) & management: opaque**
- **Includes: patients with compensated cirrhosis or non-cirrhotic CLD, who had a first episode of acute liver deterioration due to an acute insult directed to the liver**
- **Defines ACLF as “acute hepatic insult manifesting as jaundice (bilirubin \geq 5 mg/dl) and coagulopathy (INR \geq 1.5) complicated within 4 weeks by clinical ascites, HE, or both”**
- **Excludes: Extrahepatic precipitants; OFs involving kidney, respiration, circulation.**

Key Takeaways

- **For patients hospitalized with acutely decompensated cirrhosis, the EASL-CLIF definition of ACLF should be used (evidence-based definition, considers the function of 6 major organ systems, covers a large spectrum of severity).**
- **The NACSELD definition of ACLF mainly applies to ICU patients with acutely decompensated cirrhosis.**
- **The APASL definition applies to patients who are different from those considered in EASL-CLIF and NACSELD definitions.**

Can we Reconcile the Definitions?

- **Kulkarni & Sarin hypothesis:**
 - **APASL-ACLF: Early stages**
 - **EASL-CLIF ACLF: Intermediate stages**
 - **NACSELD ACLF: Late stages**
- **Large international prospective longitudinal studies are needed.**

Kulkarni & Sarin. J Hepatol. 2024 Aug;81:360-66.

Outline

- **Epidemiology**

Global Burden of ACLF

- **Meta-analysis of 30 cohorts using EASL-CLIF criteria; ~190,000 patients hospitalized for decompensated cirrhosis**
- **5 in 10 patients had alcohol-related cirrhosis; 3 in 10 patients had viral cause**
- **4 in 10 patients had ACLF**
- **6 in 10 patients with ACLF died by 90 days vs. 1 in 10 patients without ACLF**

Global Burden of ACLF

- **Meta-analysis of 30 cohorts using EASL-CLIF criteria; patients hospitalized for decompensated**
- **This study shows that the global burden of ACLF is high.**
- **However, it used both prospective and retrospective studies; no information on MASLD & new Rx.**
- **Large national & international, granular, prospective epidemiological studies are needed.**

10 patients without ACLF

Outline


- **Pathophysiology**

Systemic Inflammation

- **Assessed in blood: leukocyte count, CRP levels, cytokine levels**
 - **Exists in any form of acutely decompensated cirrhosis**
 - **Is more intense with ACLF than without ACLF**
 - **Is more intense in ACLF-3 than ACLF-1 or -2**
 - **Is less intense when ACLF improves**

Intense systemic inflammation is a major driver of ACLF development

Model for ACLF Pathophysiology



Outline

- **Management**

Medical Management


Principles

- **Diagnose acute precipitants & treat them urgently**
- **Provide supportive Tx in ICU or intermediate care unit**
- **Objective: Bridge to liver transplantation**

Treating precipitants

(acute infections, alcohol-related hepatitis)

Empiric Broad-Spectrum Antibiotics & Risk of Death Among Infected Patients with ACLF (PREDICT Study)




EASL CPG Recommendation

- **Patients with ACLF and suspicion of bacterial infections should receive broad-spectrum, empirical antibiotic therapy according to local epidemiology as soon as possible.**

EASL CPG. J Hepatol 2023;79:461-91.

The Efficacy of Steroids for Alcohol-Related Hepatitis Depends on Baseline ACLF Grade



Sersté et al. J Hepatol 2018;69:318-24.

EASL CPG Recommendations

- **Corticosteroids are not recommended in patients with ACLF-3 caused by alcohol-related hepatitis.**
- **Corticosteroids are also not recommended in patients with uncontrolled bacterial infection**

EASL CPG. J Hepatol 2023;79:461-91.


Supportive Therapies

EASL CPG Recommendations

- **The use of artificial or bioartificial extracorporeal liver support or plasma exchange in ACLF is not recommended outside investigative trials.**

EASL CPG. J Hepatol 2023;79:461-91.

Efficacy of Terlipressin for HRS-AKI Depends on Baseline Screat & ACLF Grade



Site of Admission (EASL CPG)


- **ICU:**
 - **Need for organ support (vasopressors, mechanical ventilation, or RRT)**
 - **Massive bleeding**
 - **Grade III-IV hepatic encephalopathy (airway protection)**
 - **Septic shock**
 - **Time to admission: Within the first 6 h after diagnosis**
- **Intermediate care:**
 - **Variceal bleeding**
 - **Grade II-III hepatic encephalopathy**
 - **Sepsis with HRS-AKI or with liver or coagulation failures**

EASL CPG Recommendations

- **The risk of death should be evaluated 3-7 days after starting full organ support and not at admission**

EASL CPG. J Hepatol 2023;79:461-91.

6-Month Survival After Early (<28 days) Liver Transplantation for ACLF-2 or -3




EASL CPG Recommendations

- **An early assessment for liver transplantation should be proposed for all patients with severe ACLF (ACLF-2 or -3).**
- **Defining criteria for futile liver transplantation in patients with ACLF-3 is an urgent medical need.**

EASL CPG. J Hepatol 2023;79:461-91.

Outline

- **Terminology**
- **Epidemiology**
- **Pathophysiology**
- **Management**
- **Research agenda**



**EASL CPG.
J Hepatol 2023;
79:461-91.**

Conclusions

- **The European definition of ACLF is evidence-based & widely used.**
- **ACLF is the most severe form of acutely decompensated cirrhosis.**
- **Systemic inflammation is a key pathogenic mechanism.**
- **Medical management should be urgently started against precipitants & failing organs.**
- **Early liver transplantation for ACLF-2, -3 seems effective but limited due to narrow time.**
- **The research agenda is busy.**